Month: July 2021

CARGOTEC CORPORATION, PRESS RELEASE, 2 JULY 2021 AT 7:00 AM EESTCargotec has completed the sale of its Navis business to technology investment firm Accel-KKR Cargotec has completed the sale of its Navis business to the US technology investment firm Accel-KKR for an enterprise value of EUR 380 million. Accel-KKR has transferred EUR 350 million of the enterprise value to Cargotec and obtained control of Navis’ business. The remaining EUR 30 million of the enterprise value will be transferred to Cargotec by the end of 2021. The transition of Navis operations and employees to Accel-KKR takes place in phases before the end of 2021, subject to local legal requirements. Cargotec estimates that the transaction will have approximately EUR 240 million positive impact on its operating profit in 2021. On its 26 March 2021 release, Cargotec estimated...

BEIJING, China, July 02, 2021 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI), an innovator in China’s new energy vehicle market, today announced that the Company delivered 7,713 Li ONEs in June 2021, representing a 320.6% year-over-year increase, a 78.4% quarter-over-quarter increase, and a new monthly high. As the 2021 Li ONE continues to gain traction rapidly and drive a surge in orders, the Company’s new orders in June, which surpassed 10,000, also hit a record high. Total deliveries for the second quarter increased 166.1% year-over-year and 39.7% quarter-over-quarter to reach an all-time high of 17,575, exceeding the top end of the Company’s guidance range. “On the day that marks Li Auto’s sixth anniversary, I’m pleased to share with you that thanks to strong user endorsement for the 2021 Li...

BEIJING, July 02, 2021 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced a new partnership with the World Economic Forum (WEF), under its Health and Healthcare Platform. Genetron Health, as a platform partner, will contribute its research insights, technologies, and industry experience to future projects with the WEF through the “Platform of Shaping the Future of Health and Healthcare”. Being one of WEF’s industry engagement platforms, its goal is to ensure worldwide equal access to the highest standards of health and healthcare, by helping stakeholders keep populations healthy and deliver the...

CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 14,000,000 shares of common stock at a public offering price of $25.00 per share. The gross proceeds to Cerevel of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $350 million. The offering is expected to close on July 7, 2021, subject to customary closing conditions. In addition, Cerevel has granted the underwriters a 30-day option to purchase an additional 2,100,000 shares of its common stock, at the public offering price, less underwriting discounts and commissions. J.P....

SHANGHAI, China, July 02, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has appointed Mr. Wei Qian as Chief Commercial Officer (CCO). Mr. Qian will be responsible for the company’s commercialization planning and operations. “We are delighted to have Wei join Junshi’s senior leadership team,” said Mr. Jun Xiong, Chairman of Junshi Biosciences. “Wei has over two decades of pharmaceutical sales and marketing experience. We believe he will lead Junshi Biosciences’ commercialization to our next great milestone. By leveraging a differentiation strategy, he will advance the company to meet the unmet needs of patients in China and the world.” “At...

HOUSTON, July 01, 2021 (GLOBE NEWSWIRE) — Itafos Inc. (TSX-V: IFOS) (the “Company”) announced today that Conda completed its scheduled plant turnaround during June 2021 and has returned to full production capacity. “We are pleased to have completed our full scope plant turnaround, which included certain activities that had been deferred following our decision to conduct a reduced scope plant turnaround in 2020 as part of our COVID-19 risk mitigation measures. Our team at Conda continues to demonstrate a safety-first approach to operational excellence and we look forward to continuing to deliver quality phosphate fertilizer products to our customers,” said Tim Vedder, General Manager of Conda. Conda’s plant turnaround was completed on schedule and within budget. The plant turnaround focused on inspection, testing, repair and preventative...

HOUSTON, July 01, 2021 (GLOBE NEWSWIRE) — Kayne Anderson Energy Infrastructure Fund, Inc. (the “Company”) (NYSE: KYN) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of June 30, 2021. As of June 30, 2021, the Company’s net assets were $1.2 billion, and its net asset value per share was $9.49. As of June 30, 2021, the Company’s asset coverage ratio under the 1940 Act with respect to senior securities representing indebtedness was 452% and the Company’s asset coverage ratio under the 1940 Act with respect to total leverage (debt and preferred stock) was 355%. Kayne Anderson Energy Infrastructure Fund, Inc.Statement of Assets and LiabilitiesJune 30, 2021(Unaudited)    (in...

HOUSTON, July 01, 2021 (GLOBE NEWSWIRE) — Kayne Anderson NextGen Energy & Infrastructure, Inc. (the “Fund”) (NYSE: KMF) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of June 30, 2021. As of June 30, 2021, the Fund’s net assets were $424 million and its net asset value per share was $8.99. As of June 30, 2021, the Fund’s asset coverage ratio under the 1940 Act with respect to senior securities representing indebtedness was 461% and the Fund’s asset coverage ratio under the 1940 Act with respect to total leverage (debt and preferred stock) was 374%.     Kayne Anderson NextGen Energy & Infrastructure, Inc.Statement of Assets and LiabilitiesJune 30, 2021(Unaudited)    (in...

HOUSTON, July 01, 2021 (GLOBE NEWSWIRE) — Itafos Inc. (TSX-V: IFOS) (the “Company”) announced today that it has completed a redomiciliation from the Cayman Islands to the United States. “We are pleased to have completed our redomiciliation to the United States, where most of our operations, customers, employees and contractors are located,” said G. David Delaney, CEO of Itafos. “This transaction further improves the efficiency of our corporate structure.” The redomiciliation was implemented as a continuation of the Company’s jurisdiction of incorporation from the Cayman Islands to the State of Delaware. In connection with the redomiciliation, the Company has changed its name from Itafos to Itafos Inc. The Company received all required approvals and consents to implement the redomiciliation, including approval by the Company’s shareholders...

Management works to advance its BLA filing seeking FDA approval for leronlimab as a combination therapy for HIV patients while continuing its evaluation of other potential indications VANCOUVER, Washington, July 01, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it has submitted a dose justification report to the U.S. Food and Drug Administration (“FDA”), which will be followed by an official submission to CytoDyn’s IND. This is an integral step in the resubmission process for the Biologics License Application (“BLA”) for HIV patients with multiple resistance to current standard of care. The dose justification report is a key...